Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
暂无分享,去创建一个
K. Hayashi | M. Yamagishi | H. Mabuchi | A. Nohara | M. Kawashiri | Akihiro Inazu | H. Tada | T. Higashikata | T. Konno | K. Sakata | C. Nakanishi | H. Okada
[1] M. Yamagishi,et al. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia , 2017, European heart journal.
[2] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[3] S. Humphries,et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. , 2016, The lancet. Diabetes & endocrinology.
[4] N. Seidah,et al. Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor* , 2015, The Journal of Biological Chemistry.
[5] K. Hayashi,et al. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. , 2015, The American journal of cardiology.
[6] F. Raal,et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[7] Kathleen F. Kerr,et al. Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.
[8] S. Yamashita,et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. , 2012, Journal of atherosclerosis and thrombosis.
[9] K. Hayashi,et al. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. , 2012, The American journal of cardiology.
[10] J. Kastelein,et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. , 2008, Journal of the American College of Cardiology.
[11] C. Gieger,et al. Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study , 2008, PloS one.
[12] A. Zwinderman,et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.
[13] H. Gylling,et al. Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols. , 2005, The American journal of cardiology.
[14] H. Mabuchi,et al. Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[15] Jonathan D. Cohen,et al. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. , 2003, The Journal of clinical investigation.
[16] H. Mabuchi,et al. Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. , 2002, Atherosclerosis.
[17] M. V. van’t Hof,et al. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. , 2000, Atherosclerosis.
[18] P. Demacker,et al. The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability. , 1999, Atherosclerosis.
[19] D. Rader,et al. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. , 1993, The Journal of clinical investigation.
[20] A. Hirayama,et al. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. , 2016, The American journal of cardiology.